CLINUVEL Strategic Update - Extended
Filed with ASX · · 41 pages · English
CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An extensive version (31 slide illustrations) and executive summary (13 slide illustrations) have both been lodged with the ASX. CLINUVEL is focussing on the commercialisation of the medicinal product SCENESSE® (afamelanotide controlledrelease) for the treatment of erythropoietic protoporphyria (EPP) in the European Un
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- Media Release - CLINUVEL to Trial Innovative Drug in Stroke
- Australian TGA approves SCENESSE
- Trading Halt
- Media Release - First patient dosed in SCENESSE DNA Repair
- CLINUVEL progresses innovative DNA Repair Program
Later from Clinuvel Pharmaceuticals
- Appendix 4D Half Yearly Report
- Media Release - CLINUVEL expands DNA Repair Program
- Appendix 4C - quarterly
- Appendix 4E and Preliminary Financial Report
- CLINUVEL Delivers Record Revenues and Profit
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals